Skip to main content
. 2019 May 26;12(8):1015–1025. doi: 10.1016/j.tranon.2019.05.003

Figure 5.

Figure 5

The antitumor activity of JAKi in combination with both AKT and MEK inhibitor is enhanced human ovarian cancer cells. SKOV3 (A and B) and MDAH2774 (C and D) cells were treated with JAKi (AZD1480), AKTi (MK2206), or MEKi (AZD6244), either alone or in combination, at various concentrations. Cell viability was determined 72 hours later. (B and D) Synergistic interaction between JAKi and AKTi /MEKi on the viability of ovarian cancer cells. (E) SKOV3 cells were treated with JAKi (AZD1480, 2 μM), AKTi (MK2206, 10 μM), or MEKi (AZD6244, 10 μM), either alone or together, for 48 hours. Apoptosis was determined by flow cytometry using annexin V and PI staining. **, P < .005; ***, P < .0005, combination vs. control, alone or combination of two.